Jazz Pharmaceuticals (STU:J7Z) Asset Impairment Charge : €0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Jazz Pharmaceuticals Asset Impairment Charge?

Jazz Pharmaceuticals's Asset Impairment Charge for the three months ended in Sep. 2024 was €0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was €0 Mil.

Jazz Pharmaceuticals Asset Impairment Charge Historical Data

The historical data trend for Jazz Pharmaceuticals's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Asset Impairment Charge Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

111.91

126.16

55.95

Jazz Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Jazz Pharmaceuticals Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Jazz Pharmaceuticals Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (STU:J7Z) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

JAZZ:USA J7Z:Germany

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals Headlines

No Headlines